Charlotte D. B.
- Country
- Belgium
- Department
- Thoracic Oncology
Research Overview
- Phase 3 Study of Pumitamig Versus Pembrolizumab in Previously Untreated Advanced Non-Small Cell Lung Cancer with PD-L1 ≥50%
- IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
Data & Insights
Has run more than one trial at 16 of 136 partner sites.
Specializations
Thoracic oncology and lung cancer
Charlotte De Bondt is involved in clinical research in thoracic oncology, with a clear focus on non-small cell lung cancer and related advanced disease settings. Her trial activity also extends to molecularly defined lung cancer populations and treatment-resistant disease.
- Non-small cell lung cancer
- EGFR-mutated lung cancer
- KRAS G12C-positive advanced lung cancer
- Small cell lung cancer
Her work reflects a therapeutic interest in targeted and immunotherapy-based approaches for advanced thoracic malignancies.
Breast cancer and HER2-directed therapy
Her research landscape includes a strong commitment to breast cancer, particularly HER2-positive, HER2-negative, and triple-negative breast cancer across early, locally advanced, and metastatic settings.
- HER2-positive breast cancer
- Triple-negative breast cancer
- Hormone receptor-positive breast cancer
- HER2-low breast cancer
She is also involved in studies centered on adjuvant endocrine therapy, CDK4/6 inhibition, and antibody-drug conjugate strategies.
Hematologic malignancies
A major part of her clinical research activity is concentrated in hematologic malignancies, including aggressive and indolent lymphoma, multiple myeloma, and myelodysplastic syndromes.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Multiple myeloma
- Myelodysplastic syndromes
Her portfolio also includes chronic lymphocytic leukemia, mantle cell lymphoma, myelofibrosis, and other blood cancers requiring modern immunotherapy or targeted treatment options.
Genitourinary oncology and prostate cancer
She is active in genitourinary oncology, with a strong emphasis on prostate cancer in localized, oligometastatic, and metastatic forms, as well as urothelial carcinoma and bladder cancer.
- Prostate cancer
- Metastatic castration-resistant prostate cancer
- Urothelial carcinoma
- Bladder cancer
Her trial involvement includes interest in androgen receptor-targeted treatment, radioligand therapy, and disease control in advanced urologic malignancies.
Gynecologic, gastrointestinal, and immune-mediated disease
Her research scope also covers selected solid tumors in gynecologic oncology and gastrointestinal cancer, alongside immune-mediated conditions such as rheumatoid arthritis and ulcerative colitis.
- Cervical cancer
- Ovarian cancer
- Colorectal cancer
- Rheumatoid arthritis
She is additionally involved in studies addressing melanoma, pancreatic adenocarcinoma, and inflammatory disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.